<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536016</url>
  </required_header>
  <id_info>
    <org_study_id>JO642701</org_study_id>
    <nct_id>NCT00536016</nct_id>
  </id_info>
  <brief_title>A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD</brief_title>
  <official_title>A Phase 1 Open Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeated Doses of JSM6427 Following Administration by Intravitreal Injection in Patients With Neovascular AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jerini Ophthalmic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jerini Ophthalmic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the way and rate that the study medication, JSM6427&#xD;
      a potent, highly specific integrin α5β1-antagonist is absorbed, broken-down and eliminated&#xD;
      from the body when it is given as a single dosage strength by injection into the eye.&#xD;
      Repeated dosages will also be given to determine the highest safe dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In non-clinical models, JSM6427 can lead to the inhibition and regression of choroidal&#xD;
      neovascularization, making α5β1 an attractive target for therapeutic strategies directed at&#xD;
      pathological angiogenesis. JSM6427 may also interfere with other key processes in the&#xD;
      pathogenesis of AMD, namely inflammation and fibrosis. Further, non-clinical data show that&#xD;
      JSM6427 inhibits scarring and inflammation. Thus, JSM6427 may target multiple important&#xD;
      pathways in the pathogenesis of neovascular AMD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability to determine the MTD</measure>
    <time_frame>2 weeks after each dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the systemic pharmacokinetics of JSM6427 following single and repeat doses by intravitreal injection and to assess exploratory efficacy potential of JSM6427</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JSM6427</intervention_name>
    <description>Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Best corrected visual acuity in the study eye between 5 and 7 letters inclusive using&#xD;
             and ETDRS chart (Snellen equivalent of appx. 20/800 to 20/40.&#xD;
&#xD;
          -  Subfoveal choroidal neovascularization (CNV) due to AMD.&#xD;
&#xD;
          -  Total area of the lesion (including blood, neovascularization and scar/atrophy) must&#xD;
             be ≤ 12 DA, of which at least 25% must be active CNV.&#xD;
&#xD;
          -  For patients with occult or non classic CNV; there must be the presence of subretinal&#xD;
             hemorrhage (but still comprising no more than 50% of the lesion) and/or documented&#xD;
             evidence of three or more lines of vision loss (ETDRS or equivalent) during the&#xD;
             previous 12 weeks.&#xD;
&#xD;
          -  Clear ocular media and adequate pupillary dilatation to permit good stereo fundus&#xD;
             photography for screening.&#xD;
&#xD;
          -  Intraocular pressure of 21 mm Hg or less.&#xD;
&#xD;
          -  Retinal thickness ≥ 250 μm by OCT.&#xD;
&#xD;
          -  Normal screening ERG&#xD;
&#xD;
          -  Normal ECG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PDT within 120 days prior to screening in the study eye.&#xD;
&#xD;
          -  Previous therapeutic radiation to the eye.&#xD;
&#xD;
          -  Any retinovascular disease or retinal degeneration other than AMD.&#xD;
&#xD;
          -  Serous pigment epithelial detachment without the presence of neovascularization.&#xD;
&#xD;
          -  Presence of pigment epithelial tears or rips.&#xD;
&#xD;
          -  Previous posterior vitrectomy or retinal surgery.&#xD;
&#xD;
          -  Any periocular infection in the past 4 weeks.&#xD;
&#xD;
          -  Concomitant therapy with anti-VEGF therapies, e.g. Avastin, Lucentis or Macugen, or&#xD;
             previous use of these agents within 60 days of screening in the study eye.&#xD;
&#xD;
          -  Concomitant therapy with intravenous or intravitreous corticosteroids or use within 90&#xD;
             days of screening.&#xD;
&#xD;
          -  Cataract surgery in the study eye within three months of screening.&#xD;
&#xD;
          -  Intraocular surgery in the study eye within three months of screening.&#xD;
&#xD;
          -  Presence of ocular infection in the study eye.&#xD;
&#xD;
          -  Presence of severe myopia (-8 diopters or greater) in the study eye.&#xD;
&#xD;
          -  Allergy to or prior significant adverse reaction to fluorescein.&#xD;
&#xD;
          -  Any major surgical procedure within one month of trial entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Adamis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jerini Ophthalmic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Research Institute</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>40873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Retina Center</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Institute of Texas</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreoretinal Consultants</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>September 25, 2007</study_first_submitted>
  <study_first_submitted_qc>September 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2007</study_first_posted>
  <last_update_submitted>September 20, 2010</last_update_submitted>
  <last_update_submitted_qc>September 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2010</last_update_posted>
  <responsible_party>
    <organization>Jerini Ophthalmic</organization>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Neovascular Age-Related Macular Degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

